{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:54:01Z","timestamp":1773431641471,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012521","name":"Universitas Gadjah Mada","doi-asserted-by":"crossref","award":["Riset Kolaborasi Indonesia \u2013 Worlds Class University 2022 (contract no.1550\/UN1\/DITLIT\/DIT-LIT\/PT.01.03\/2022)."],"award-info":[{"award-number":["Riset Kolaborasi Indonesia \u2013 Worlds Class University 2022 (contract no.1550\/UN1\/DITLIT\/DIT-LIT\/PT.01.03\/2022)."]}],"id":[{"id":"10.13039\/501100012521","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00621-4","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T13:25:10Z","timestamp":1751808310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A computational study of cardiac glycosides from Vernonia amygdalina as PI3K inhibitors for targeting HER2 positive breast cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Ahmad Syauqy","family":"Tafrihani","sequence":"first","affiliation":[]},{"given":"Naufa","family":"Hanif","sequence":"additional","affiliation":[]},{"given":"I Made Bayu Kresna","family":"Yoga","sequence":"additional","affiliation":[]},{"given":"Irmasari","family":"Irmasari","sequence":"additional","affiliation":[]},{"given":"Taufik Muhammad","family":"Fakih","sequence":"additional","affiliation":[]},{"given":"Dhania","family":"Novitasari","sequence":"additional","affiliation":[]},{"given":"Poppy Anjelisa Zaitun","family":"Hasibuan","sequence":"additional","affiliation":[]},{"given":"Denny","family":"Satria","sequence":"additional","affiliation":[]},{"given":"Fathul","family":"Huda","sequence":"additional","affiliation":[]},{"given":"Muchtaridi","family":"Muchtaridi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3691","authenticated-orcid":false,"given":"Adam","family":"Hermawan","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"1270877","DOI":"10.3389\/fonc.2023.1270877","volume":"13","author":"P Contiero","year":"2023","unstructured":"Contiero P, Boffi R, Borgini A, Fabiano S, Tittarelli A, Mian M et al (2023) Causes of death in women with breast cancer: a risks and rates study on a population-based cohort. Front Oncol 13:1270877","journal-title":"Front Oncol"},{"key":"621_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082081","author":"A Patel","year":"2020","unstructured":"Patel A, Unni N, Peng Y (2020) The changing paradigm for the treatment of HER2-positive breast cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers12082081","journal-title":"Cancers"},{"issue":"1","key":"621_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41523-020-00201-9","volume":"6","author":"Z Yi","year":"2020","unstructured":"Yi Z, Rong G, Guan Y, Li J, Chang L, Li H et al (2020) Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. NPJ Breast Cancer 6(1):59. https:\/\/doi.org\/10.1038\/s41523-020-00201-9","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"621_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10911-014-9329-5","volume":"19","author":"A Dittrich","year":"2014","unstructured":"Dittrich A, Gautrey H, Browell D, Tyson-Capper A (2014) The HER2 signaling network in breast cancer\u2014like a spider in its web. J Mammary Gland Biol Neoplasia 19(3):253\u2013270. https:\/\/doi.org\/10.1007\/s10911-014-9329-5","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","volume":"45","author":"EC Lien","year":"2017","unstructured":"Lien EC, Dibble CC, Toker A (2017) PI3K signaling in cancer: beyond AKT. Curr Opin Cell Biol 45:62\u201371. https:\/\/doi.org\/10.1016\/j.ceb.2017.02.007","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"621_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","volume":"22","author":"O Mart\u00ednez-S\u00e1ez","year":"2020","unstructured":"Mart\u00ednez-S\u00e1ez O, Chic N, Pascual T, Adamo B, Vidal M, Gonz\u00e1lez-Farr\u00e9 B et al (2020) Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res 22(1):45. https:\/\/doi.org\/10.1186\/s13058-020-01284-9","journal-title":"Breast Cancer Res"},{"issue":"1","key":"621_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/biomedicines11010109","volume":"11","author":"K Cerma","year":"2023","unstructured":"Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A et al (2023) Targeting PI3K\/AKT\/mTOR pathway in breast cancer: from biology to clinical challenges. Biomedicines 11(1):109","journal-title":"Biomedicines"},{"issue":"35","key":"621_CR8","doi-asserted-by":"publisher","first-page":"eabj4282","DOI":"10.1126\/sciadv.abj4282","volume":"7","author":"MK Rathinaswamy","year":"2021","unstructured":"Rathinaswamy MK, Dalwadi U, Fleming KD, Adams C, Stariha JTB, Pardon E et al (2021) Structure of the phosphoinositide 3-kinase (PI3K) p110\u03b3-p101 complex reveals molecular mechanism of GPCR activation. Sci Adv 7(35):eabj4282. https:\/\/doi.org\/10.1126\/sciadv.abj4282","journal-title":"Sci Adv"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.3390\/ijms19123931","volume":"19","author":"F Gavgani","year":"2018","unstructured":"Gavgani F, Arnesen V, Jacobsen R, Krakstad C, Hoivik E, Lewis A (2018) Class I phosphoinositide 3-kinase PIK3CA\/p110\u03b1 and PIK3CB\/p110\u03b2 isoforms in endometrial cancer. Int J Mol Sci 19:3931. https:\/\/doi.org\/10.3390\/ijms19123931","journal-title":"Int J Mol Sci"},{"issue":"4","key":"621_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K pathway in human disease. Cell 170(4):605\u2013635. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"key":"621_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163949","author":"F Rascio","year":"2021","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS et al (2021) The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers. https:\/\/doi.org\/10.3390\/cancers13163949","journal-title":"Cancers"},{"issue":"24","key":"621_CR12","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","volume":"65","author":"EJ Hanan","year":"2022","unstructured":"Hanan EJ, Braun M-G, Heald RA, MacLeod C, Chan C, Clausen S et al (2022) Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3K\u03b1. J Med Chem 65(24):16589\u201316621. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01422","journal-title":"J Med Chem"},{"issue":"23","key":"621_CR13","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-15-3051","volume":"22","author":"A Soler","year":"2016","unstructured":"Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A et al (2016) Therapeutic benefit of selective inhibition of p110\u03b1 PI3-Kinase in pancreatic neuroendocrine tumors. Clin Cancer Res 22(23):5805\u20135817. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3051","journal-title":"Clin Cancer Res"},{"issue":"6","key":"621_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JCO.2023.41.6_suppl.149","volume":"41","author":"A Sen","year":"2023","unstructured":"Sen A, Khan SA, MacNeil IA, Rich BE, Molden JS, Davis LN et al (2023) Therapeutic effect of gedatolisib, a pan-PI3K\/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status. J Clin Oncol 41(6):149. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.149","journal-title":"J Clin Oncol"},{"issue":"1","key":"621_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.canlet.2012.08.020","volume":"328","author":"H Lee","year":"2013","unstructured":"Lee H, Jung KH, Jeong Y, Hong S, Hong S-S (2013) HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett 328(1):152\u2013159. https:\/\/doi.org\/10.1016\/j.canlet.2012.08.020","journal-title":"Cancer Lett"},{"key":"621_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.659511","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Shen H, Sun Q, Zhao L, Liu H, Ye L et al (2021) The new PI3K\/mTOR inhibitor GNE-477 inhibits the malignant behavior of human glioblastoma cells. Front Pharmacol 12:659511. https:\/\/doi.org\/10.3389\/fphar.2021.659511","journal-title":"Front Pharmacol"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"175883592094093","DOI":"10.1177\/1758835920940939","volume":"12","author":"P du Rusquec","year":"2020","unstructured":"du Rusquec P, Blonz C, Frenel JS, Campone M (2020) Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Ther Adv Med Oncol 12:1758835920940939. https:\/\/doi.org\/10.1177\/1758835920940939","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"621_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12935-024-03258-9","volume":"24","author":"T Cai","year":"2024","unstructured":"Cai T, Feng T, Li G, Wang J, Jin S, Ye D et al (2024) Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75. Cancer Cell Int 24(1):125. https:\/\/doi.org\/10.1186\/s12935-024-03258-9","journal-title":"Cancer Cell Int"},{"issue":"17","key":"621_CR19","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.Ccr-16-2888","volume":"23","author":"D Juric","year":"2017","unstructured":"Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL et al (2017) A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3K\u03b1 isoform inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 23(17):5015\u20135023. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2888","journal-title":"Clin Cancer Res"},{"issue":"5","key":"621_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1421890","volume":"7","author":"J-H Choi","year":"2018","unstructured":"Choi J-H, Kim KH, Roh K-H, Jung H, Lee A, Lee J-Y et al (2018) A PI3K p110\u03b1-selective inhibitor enhances the efficacy of anti-HER2\/neu antibody therapy against breast cancer in mice. OncoImmunology 7(5):e1421890. https:\/\/doi.org\/10.1080\/2162402X.2017.1421890","journal-title":"OncoImmunology"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"3159352","DOI":"10.1155\/2023\/3159352","volume":"2023","author":"D-B Asante","year":"2023","unstructured":"Asante D-B, Wiafe GA (2023) Therapeutic benefit of Vernonia amygdalina in the treatment of diabetes and its associated complications in preclinical studies. J Diabetes Res 2023:3159352. https:\/\/doi.org\/10.1155\/2023\/3159352","journal-title":"J Diabetes Res"},{"issue":"3","key":"621_CR22","first-page":"2629","volume":"8","author":"D Kaur","year":"2019","unstructured":"Kaur D, Kaur N, Chopra A (2019) A comprehensive review on phytochemistry and pharmacological activities of Vernonia amygdalina. J Pharmacognosy Phytochem 8(3):2629\u20132636","journal-title":"J Pharmacognosy Phytochem"},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.71.e125788","volume":"71","author":"PAZ Hasibuan","year":"2024","unstructured":"Hasibuan PAZ, Sitorus RKUAB, Hermawan A, Huda F, Waruwu SB, Satria D (2024) Anticancer activity of the ethylacetate fraction of Vernonia amygdalina Delile towards overexpression of HER-2 breast cancer cell lines. Pharmacia 71:1\u20138","journal-title":"Pharmacia"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.sajb.2023.12.002","volume":"164","author":"A Hermawan","year":"2024","unstructured":"Hermawan A, Satria D, Hasibuan PAZ, Huda F, Tafrihan AS, Fatimah N et al (2024) Identification of potential target genes of cardiac glycosides from Vernonia amygdalina Delile in HER2+ breast cancer cells. S Afr J Bot 164:401\u2013418","journal-title":"S Afr J Bot"},{"issue":"10","key":"621_CR25","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.31557\/APJCP.2024.25.10.3589","volume":"25","author":"F Huda","year":"2024","unstructured":"Huda F, Bashari MH, Satria D, Hermawan A, Hasibuan PAZ, Dwiwina RG et al (2024) Cancer chemotherapeutic effect of Vernonia amygdalina Delile on glioblastoma brain cancer cell. Asian Pac J Cancer Prev 25(10):3589\u20133595","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"621_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e04449","volume":"6","author":"PAZ Hasibuan","year":"2020","unstructured":"Hasibuan PAZ, Harahap U, Sitorus P, Satria D (2020) The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway. Heliyon 6(7):e04449. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04449","journal-title":"Heliyon"},{"issue":"2","key":"621_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acs.chemrestox.0c00511","volume":"34","author":"S Jain","year":"2021","unstructured":"Jain S, Norinder U, Escher SE, Zdrazil B (2021) Combining in vivo data with in silico predictions for modeling hepatic steatosis by using stratified bagging and conformal prediction. Chem Res Toxicol 34(2):656\u2013668. https:\/\/doi.org\/10.1021\/acs.chemrestox.0c00511","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"621_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40199-023-00484-w","volume":"32","author":"G Yuda","year":"2024","unstructured":"Yuda G, Hanif N, Hermawan A (2024) Computational screening using a combination of ligand-based machine learning and molecular docking methods for the repurposing of antivirals targeting the SARS-CoV-2 main protease. Daru 32(1):47\u201365. https:\/\/doi.org\/10.1007\/s40199-023-00484-w","journal-title":"Daru"},{"issue":"14","key":"621_CR29","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM, Carchia M, Irwin JJ, Shoichet BK (2012) Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55(14):6582\u20136594. https:\/\/doi.org\/10.1021\/jm300687e","journal-title":"J Med Chem"},{"issue":"Suppl 1","key":"621_CR30","first-page":"66","volume":"77","author":"AD Anggraeni","year":"2022","unstructured":"Anggraeni AD, Salsabila DU, Anggoro B, Hermawan A (2022) Network pharmacology for deciphering molecular mechanism of mahogany in dyslipidemia treatment of menopausal conditions. Med J Malaysia 77(Suppl 1):66\u201377","journal-title":"Med J Malaysia"},{"issue":"2","key":"621_CR31","first-page":"347","volume":"13","author":"\u0130 Ate\u015f","year":"2021","unstructured":"Ate\u015f \u0130, Bilgin TT (2021) The investigation of the success of different machine learning methods in breast cancer diagnosis. Konuralp Med J 13(2):347\u2013356","journal-title":"Konuralp Med J"},{"issue":"1","key":"621_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.aichem.2024.100063","volume":"2","author":"R Joshi","year":"2024","unstructured":"Joshi R, Zheng Z, Agarwal P, MmM Hatmal, Chang X, Seidler P et al (2024) KNIME workflows for applications in medicinal and computational chemistry. Artif Intell Chem 2(1):100063. https:\/\/doi.org\/10.1016\/j.aichem.2024.100063","journal-title":"Artif Intell Chem"},{"issue":"5","key":"621_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.31557\/APJCP.2024.25.5.1623","volume":"25","author":"IA Lestari","year":"2024","unstructured":"Lestari IA, Putra I, Fatimah N, Ujiantari NSO, Putri DDP, Hermawan A (2024) Characterization of potential target genes of borneol in increasing trastuzumab sensitivity in HER2+ trastuzumab-resistant breast cancer: bioinformatics and in vitro studies. Asian Pac J Cancer Prev 25(5):1623\u20131634","journal-title":"Asian Pac J Cancer Prev"},{"issue":"16","key":"621_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005) GROMACS: fast, flexible, and free. J Comput Chem 26(16):1701\u20131718","journal-title":"J Comput Chem"},{"issue":"11","key":"621_CR35","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29(11):1859\u20131865","journal-title":"J Comput Chem"},{"key":"621_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2329302","author":"N Hanif","year":"2024","unstructured":"Hanif N, Sari S (2024) Discovery of novel IDO1\/TDO2 dual inhibitors: a consensus virtual screening approach with molecular dynamics simulations, and binding free energy analysis. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2024.2329302","journal-title":"J Biomol Struct Dyn"},{"issue":"7963","key":"621_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05972-2","volume":"618","author":"GQ Gong","year":"2023","unstructured":"Gong GQ, Bilanges B, Allsop B, Masson GR, Roberton V, Askwith T et al (2023) A small-molecule PI3K\u03b1 activator for cardioprotection and neuroregeneration. Nature 618(7963):159\u2013168","journal-title":"Nature"},{"issue":"1","key":"621_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s1056-8719(00)00107-6","volume":"44","author":"CA Lipinski","year":"2000","unstructured":"Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44(1):235\u2013249. https:\/\/doi.org\/10.1016\/s1056-8719(00)00107-6","journal-title":"J Pharmacol Toxicol Methods"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/dti.S12519","volume":"7","author":"ML Amin","year":"2013","unstructured":"Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27\u201334. https:\/\/doi.org\/10.4137\/dti.S12519","journal-title":"Drug Target Insights"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.phytol.2015.11.002","volume":"15","author":"O Quasie","year":"2016","unstructured":"Quasie O, Zhang Y-M, Zhang H-J, Luo J, Kong L-Y (2016) Four new steroid saponins with highly oxidized side chains from the leaves of Vernonia amygdalina. Phytochem Lett 15:16\u201320","journal-title":"Phytochem Lett"},{"issue":"3","key":"621_CR41","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/molecules23030579","volume":"23","author":"J Wang","year":"2018","unstructured":"Wang J, Song H, Wu X, Zhang S, Gao X, Li F et al (2018) Steroidal saponins from Vernonia amygdalina Del and their biological activity. Molecules 23(3):579","journal-title":"Molecules"},{"issue":"53","key":"621_CR42","doi-asserted-by":"publisher","first-page":"33380","DOI":"10.1039\/D1RA05976A","volume":"11","author":"OM Ogunyemi","year":"2021","unstructured":"Ogunyemi OM, Gyebi GA, Ibrahim IM, Olaiya CO, Ocheje JO, Fabusiwa MM et al (2021) Dietary stigmastane-type saponins as promising dual-target directed inhibitors of SARS-CoV-2 proteases: a structure-based screening. RSC Adv 11(53):33380\u201333398","journal-title":"RSC Adv"},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10822-016-0005-2","volume":"31","author":"K Liu","year":"2017","unstructured":"Liu K, Watanabe E, Kokubo H (2017) Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. J Comput Aided Mol Des 31:201\u2013211","journal-title":"J Comput Aided Mol Des"},{"issue":"4","key":"621_CR44","first-page":"701","volume":"42","author":"MIu L, Bogatyreva N, Galzitskaia O","year":"2008","unstructured":"MIu L, Bogatyreva N, Galzitskaia O (2008) Radius of gyration is indicator of compactness of protein structure. Molekuliarnaia Biologiia 42(4):701\u20136","journal-title":"Molekuliarnaia Biologiia"},{"issue":"14","key":"621_CR45","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1200\/jco.21.01648","volume":"40","author":"S Damodaran","year":"2022","unstructured":"Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ et al (2022) Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F. J Clin Oncol 40(14):1552\u20131561. https:\/\/doi.org\/10.1200\/jco.21.01648","journal-title":"J Clin Oncol"},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/978-981-10-4166-2_58","volume-title":"CMBEBIH 2017","author":"J Olui\u0107","year":"2017","unstructured":"Olui\u0107 J, Nikolic K, Vucicevic J, Gagic Z, Filipic S, Agbaba D (2017) QSAR modeling and structure based virtual screening of new PI3K\/mTORinhibitors as potential anticancer agents. In: Badnjevic A (ed) CMBEBIH 2017. Springer, Singapore, pp 379\u2013383"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00621-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:45Z","timestamp":1762451805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00621-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00621-4","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,6]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}